Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation. Brainsway Ltd. was founded in 2003 and is based in Jerusalem, Israel.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone972-2581-3140
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees96
Next Earnings DateN/A
OptionableNot Optionable
BRAINSWAY LTD/S (NASDAQ:BWAY) Frequently Asked Questions
What is BRAINSWAY LTD/S's stock symbol?
BRAINSWAY LTD/S trades on the NASDAQ under the ticker symbol "BWAY."
How were BRAINSWAY LTD/S's earnings last quarter?
BRAINSWAY LTD/S (NASDAQ:BWAY) posted its quarterly earnings data on Wednesday, May, 29th. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.02. The business earned $5.18 million during the quarter, compared to analyst estimates of $5 million. View BRAINSWAY LTD/S's Earnings History.
What price target have analysts set for BWAY?
5 brokerages have issued 12-month target prices for BRAINSWAY LTD/S's stock. Their predictions range from $14.00 to $19.00. On average, they expect BRAINSWAY LTD/S's share price to reach $16.75 in the next year. This suggests a possible upside of 93.4% from the stock's current price. View Analyst Price Targets for BRAINSWAY LTD/S.
What is the consensus analysts' recommendation for BRAINSWAY LTD/S?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BRAINSWAY LTD/S in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BRAINSWAY LTD/S.
Has BRAINSWAY LTD/S been receiving favorable news coverage?
Media stories about BWAY stock have trended somewhat positive on Monday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BRAINSWAY LTD/S earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for BRAINSWAY LTD/S.
Who are some of BRAINSWAY LTD/S's key competitors?
Some companies that are related to BRAINSWAY LTD/S include Vapotherm (VAPO), Accuray (ARAY), Utah Medical Products (UTMD), Westaim (WEDXF), Pulse Biosciences (PLSE), SeaSpine (SPNE), Inovio Pharmaceuticals (INO), Iradimed (IRMD), Alphatec (ATEC), Soliton (SOLY), Apyx Medical (APYX), Neuronetics (STIM), Cytosorbents (CTSO), Liquidia Technologies (LQDA) and Endologix (ELGX).
What other stocks do shareholders of BRAINSWAY LTD/S own?
Who are BRAINSWAY LTD/S's key executives?
BRAINSWAY LTD/S's management team includes the folowing people:
- Dr. David Zacut, Founder & Chairman (Age 66)
- Prof. Abraham Zangen, Founder & Member of the Scientific Advisory Board (Age 49)
- Dr. Yiftach Roth, Founder & Chief Scientist (Age 48)
- Mr. Hadar Levy, Chief Financial Officer (Age 45)
- Mr. Ronen Segal, Chief Technology Officer (Age 46)
When did BRAINSWAY LTD/S IPO?
(BWAY) raised $30 million in an initial public offering on Wednesday, April 17th 2019. The company issued 2,500,000 shares at a price of $11.94 per share. Cantor acted as the underwriter for the IPO.
When does BRAINSWAY LTD/S's lock-up period expire?
BRAINSWAY LTD/S's lock-up period expires on Monday, October 14th. BRAINSWAY LTD/S had issued 2,500,000 shares in its public offering on April 17th. The total size of the offering was $27,500,000 based on an initial share price of $11.00. After the end of BRAINSWAY LTD/S's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
How do I buy shares of BRAINSWAY LTD/S?
Shares of BWAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BRAINSWAY LTD/S's stock price today?
One share of BWAY stock can currently be purchased for approximately $8.66.
How big of a company is BRAINSWAY LTD/S?
What is BRAINSWAY LTD/S's official website?
How can I contact BRAINSWAY LTD/S?
BRAINSWAY LTD/S's mailing address is 19 HARTUM STREET BYNET BUILDING 3RD FL, Jerusalem L3, 91451. The company can be reached via phone at 972-2581-3140 or via email at [email protected]
MarketBeat Community Rating for BRAINSWAY LTD/S (NASDAQ BWAY)
MarketBeat's community ratings are surveys of what our community members think about BRAINSWAY LTD/S and other stocks. Vote "Outperform" if you believe BWAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BWAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
